Mylan sold a ₹1,839 crore stake in Biocon through a block deal, attracting strong institutional demand. ICICI Prudential Mutual Fund emerged as the largest buyer, alongside other mutual funds, insurers and foreign investors, highlighting continued confidence in the pharmaceutical company.

Viatris plans to sell a 5.64% stake in Biocon at a 7.9% discount, marking a complete exit.

Biocon shares experienced a significant jump of over 6% on Tuesday. Viatris-owned Mylan intends to sell a substantial stake, exiting the Indian drugmaker. This stake sale…

Mylan sold a ₹1,839 crore stake in Biocon through a block deal, attracting strong institutional demand. ICICI Prudential Mutual Fund emerged as the largest buyer, alongside other…

Mylan, part of Viatris, exits Biocon by selling its 5.64% stake for ₹3,679 crore. Domestic mutual funds and global investors buy shares as Biocon gains over 6%.